著者
坂根義久著
出版者
刀水書房
巻号頁・発行日
1985
著者
藤岡 俊樹
出版者
日本神経治療学会
雑誌
神経治療学 (ISSN:09168443)
巻号頁・発行日
vol.35, no.3, pp.198-202, 2018 (Released:2018-12-25)
参考文献数
29

CIDP (chronic inflammatory demyelinating polyneuritis) is the most common immune–mediated chronic polyneuropathy that comprises typical CIDP (symmetrical demyelinating sensory–motor neuropathy) and several subtypes ; i.e., MADSAM (multifocal acquired demyelinating sensory and motor) neuropathy (Lewis Sumner Syndrome), DADS (distal acquired demyelinating symmetric) neuropathy and multifocal motor neuropathy (MMN). Typical CIDP is usually treated by either intravenous immunoglobulin (IVIg), corticosteroid (CS) or plasma exchange (PLEX). These three therapies are thought as a first line therapy (FLT). Among FLT, IVIg and CS are very often employed because of their simplicity during treatment, however, the efficacy is almost same in three modalities of FLT. If one treatment of FLT failed to lead a good response, other treatment of FLT should be tried. Finally, FLT results in remission in more than 80% of typical CIDP cases. Second line treatment for FLT–resistant cases is still vague although numerous experiences especially about immunosuppressive agents (ISA) have been reported. Among ISA, cyclophosphamide (intravenous pulse) and rituximab seem to be effective although randomized controlled trial is required. IVIg treatment requires maintenance treatment (IVIg every three weeks). Recently efficacy of subcutaneous immunoglobulin treatment (SCIg) in maintenance treatment was proven although it is not approved in Japan. Merit of SCIg is that it can be done by patients in their home. Moreover, SCIg is proven effective as an initial treatment for typical CIDP. This may help patients suffering from CIDP reduce economical, physical or time burden during treatment.The standard treatment for MADSAM neuropathy is still vague. FLT in typical CIDP should be tried as well. IVIg–responding case needs to adhere maintenance IVIg or SCIg although later is not approved in Japan.MMN responds to IVIg well, however, delayed diagnosis or treatment results in poor response.Recently, neuropathy with antibodies against proteins localized in paranode of peripheral nerve is discovered, called as “paranodopathy”.Most of these cases have IgG4 antibodies against Neurofascin 155, 140, 186, contactin–1, or contactin–associated protein 1 (Caspr). They present unique signs compared to typical CIDP, i.e., relatively rapid progression, remarkable ataxia or tremor. Most of these cases present poor response for IVIg. Rituximab seems to be a hopeful therapeutical candidate in the future although strong evidence is not available at this moment.

1 0 0 0 OA 成功の生涯

著者
奥村多喜衛 著
出版者
警醒社
巻号頁・発行日
1903
著者
Akira Hashimoto-Gotoh Koichi Kitao Takayuki Miyazawa
出版者
Japanese Society of Microbial Ecology / Japanese Society of Soil Microbiology / Taiwan Society of Microbial Ecology / Japanese Society of Plant Microbe Interactions / Japanese Society for Extremophiles
雑誌
Microbes and Environments (ISSN:13426311)
巻号頁・発行日
vol.35, no.1, pp.ME19130, 2020 (Released:2020-01-23)
参考文献数
62
被引用文献数
5

MicroRNAs (miRNAs) are a group of small non-coding RNAs that suppress the expression of target mRNAs. The seed sequence of miRNA plays a crucial role in recognizing the 3′-untranslated region of the target mRNA. Cells infected with a simian foamy virus (SFV) isolated from an African green monkey (Chlorocebus aethiops) (SFVcae) showed high expression levels of viral miRNAs encoded in the long terminal repeat of SFVcae. In the present study, we investigated the roles and expression of miRNAs derived from an SFV isolated from a Japanese macaque (Macaca fuscata) (SFVmfu) using next-generation sequencing technologies. The results obtained showed that SFVmfu also expressed viral miRNAs; however, the seed sequences of most miRNAs derived from SFVmfu differed from those reported previously from SFVcae. Cells persistently infected with SFVmfu strongly expressed an miRNA with the same seed sequence as the miR-1 microRNA precursor family. Luciferase reporter assays indicated that this miRNA down-regulates the expression of adenylyl cyclase-associated protein 1, which is up-regulated in several solid tumors. The present results suggest that SFVmfu utilizes viral miRNAs to establish long-term co-existence with the Japanese macaque.

1 0 0 0 論語

著者
吹野安 石本道明著
出版者
明徳出版社
巻号頁・発行日
1999

1 0 0 0 論語集注

著者
朱熹 [集注] 土田健次郎訳注
出版者
平凡社
巻号頁・発行日
2013
著者
江連隆著
出版者
大修館書店
巻号頁・発行日
1996
著者
高畑常信著
出版者
木耳社
巻号頁・発行日
2014

1 0 0 0 論語の世界

著者
金谷治著
出版者
日本放送出版協会
巻号頁・発行日
1970
著者
酒井 大輔 檜山 明彦 平山 令明 升井 伸治
出版者
東海大学
雑誌
基盤研究(B)
巻号頁・発行日
2016-04-01

本研究計画の目的は、椎間板髄核細胞の分化、生存を制御する転写因子ネットワークについてiPS技術を用いて解析し、未だ詳細には解明されていない、iPS細胞や間葉系幹細胞などからの椎間板髄核前駆細胞の誘導法を確立することである。その後、明らかとなったコア転写因子を用いて、髄核細胞の機能向上、コア転写因子を標的とした新規治療法の開発など椎間板再生医療研究に広く応用することである。実験1椎間板髄核細胞のiPS化:コア転写因子を同定するiPS干渉法を行うために、椎間板髄核細胞のiPS化を行った。京都大学iPS研究所のiPS化プロトコールに従いiPS細胞評価は細胞形態変化とアルカリフォスファターゼ染色にて行った。その結果、椎間板髄核細胞のiPS化が認められたが、酸素分圧の調整など検討材料が得られた。実験2椎間板髄核細胞iPS化の高効率化、遺伝子導入効率の向上:椎間板髄核細胞はiPS化したものの導出効率が低く、iPS干渉法で阻害度を測定するには不十分であったため、iPS化の高効率化を行った。GFPにて遺伝子導入効率が良い酸素分圧、培養条件を検討した。その結果、低酸素+α-MEM培地の条件にて高いGFP発現率(80%)を認め、常酸素+D-MEM培地の条件では発現率は低かった(46.2%)。そこで酸素分圧と、細胞密度を振ってiPS化工程を行った結果、全工程を低酸素条件でした群ではiPS化は起こらなかった。遺伝子導入時は低酸素条件で行い、その後は常酸素条件に戻した群で多数のiPSコロニーを認めた。これは一般的に線維芽細胞のiPS化では低酸素にてiPSコロニー数は増加することが知られているが、低酸素、HIF1A、HIF2Aは髄核細胞の特性としても非常に重要であることが知られているため、低酸素条件が髄核細胞形質を維持させたことが考えられ、新たな知見を見出した。現在、転写因子の絞り込みを行なっている。